article thumbnail

Navigating the Regulatory Environment of Pharmaceutical Marketing: Balancing Patient Safety and Industry Innovation

Pharma Marketing Network

Pharmaceutical marketing is a critical aspect of the industry, as it helps in spreading awareness about the benefits and potential side effects of different drugs. In conclusion, navigating the regulatory environment of pharmaceutical marketing requires a delicate balance between patient safety and industry innovation.

Safety 52
article thumbnail

Novel anti-epileptic drug demonstrates efficacy

European Pharmaceutical Review

A new approach to potassium-channel openers for epilepsy Critically, XEN1101 combines the effectiveness of potassium-channel openers with the safety of more traditional drugs, stated study lead author and neurologist Dr Jacqueline French. It ran between January 2019 and September 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

European approval for third adapted COVID-19 vaccine

European Pharmaceutical Review

The safety profile of the adapted vaccine is expected to be like that of the originally authorised Nuvaxovid, EMA said. The most common side effects with Nuvaxovid XBB.1.5 Nuvaxovid was first authorised in the European Union in December 2021. Based on these data, the Committee concluded that Nuvaxovid XBB.1.5

article thumbnail

Comirnaty® authorised for patients six months to four years

European Pharmaceutical Review

The common, expected side effects were within expectations for a vaccine in this age group. The Commission on Human Medicines (CHM), which endorsed the authorisation, advises ministers on the safety, efficacy and quality of medicinal products. Data that facilitated the line extension of Comirnaty ® for Covid-19.

article thumbnail

Oral drug reduces treatment-resistant migraine frequency

European Pharmaceutical Review

“These results are exciting… this treatment led to fewer days with migraine for people who had already tried up to four other types of drugs to prevent migraine and either had no improvement or had side effects that outweighed any benefits,” commented study author Dr Patricia Pozo-Rosich, PhD at Vall d’Hebron University Hospital in Barcelona, Spain.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

Such developments, including a 2021 approval of AstraZeneca’s Saphnelo (anifrolumab) , prompted The Lancet Rheumatology to posit that 2022 could be a “banner year” for the condition. The CAR-T therapies for conditions like lupus continue to look promising, but their safety is a concern, says Gilkeson. MSCs and CAR-Ts for lupus.

article thumbnail

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. There was no significant difference in side effect profiles of the two vaccines, based on the data. percentage points (96% CI, −0.3 for serogroup W to 20.5